SARomics Biostructures and Vipergen Offer DEL-based drug discovery services
SARomics Biostructures AB and Vipergen ApS partner to offer hit and lead identification services based on Vipergen’s DEL screening technology.
company news
2023 – More Structural Biology & Drug Discovery
In this article, we will discuss some significant publications and company activities in 2023. The publications showcase our expertise in the three main areas of our services: X-ray crystallography, NMR spectroscopy, and integrated drug discovery.
Aqilion’s TAK1 inhibitor secures alliance worth € 950 million
Using an integrated drug discovery approach, first-in-class TAK1 kinase inhibitors were designed in a hit-to-lead program run in close cooperation between three partners, SARomics Biostructures, Red Glead Discovery, and Aqilion.
News update June 2023
This post provides the latest company news update. It would be fair to keep our former clients, followers, and anybody…
What makes a successful CRO?
What makes a successful services company? What is our strength, and how to define our selling points? We arrive at a list of 8 essential selling points defining the success of SARomics Biostructures.
LundaGUARD – A Consortium For Fighting Infectious Agents
Several private and public organizations join efforts in the LundaGUARD consortium to respond to present and future threats from infectious…
EU-Funded Research Projects with SARomics
Since our first trip into the realm of EU projects with the KINOMED project, we have engaged in 7 different…
SARomics Biostructures 2018: A Foundation For the Future
It was a fantastic year for the company! We introduced new team members and new services, including WAC fragment screening…